stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Revenue growth
Celldex Therapeutics, Inc.'s revenue growth over the twelve months to 30 June 2026 was −88.3%, down 10.3 percentage points from fiscal 2025 (−78.0%). Over the past ten years it has ranged from −78.0% (fiscal 2025) to 192.0% (fiscal 2023) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −78.0% | (79.98) |
| FY2024 | 1.99% | (190.03) |
| FY2023 | 192.0% | 241.34 |
| FY2022 | −49.3% | (12.02) |
| FY2021 | −37.3% | (144.91) |
| FY2020 | 107.6% | 170.15 |
| FY2019 | −62.5% | (37.39) |
| FY2018 | −25.2% | (112.93) |
| FY2017 | 87.8% | 63.95 |
| FY2016 | 23.8% | (28.99) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | −96.8% | 1.89 |
| Mar 2026 | −98.7% | (2.48) |
| Dec 2025 | −96.2% | (25.46) |
| Jun 2025 | −70.8% | (416.29) |
| 41 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BHVN Biohaven Ltd. compare | 425.2% |
| PVLA Palvella Therapeutics, Inc. compare | 146.7% |
| VCEL Vericel Corporation compare | 25.3% |
| AUPH Aurinia Pharmaceuticals Inc compare | 21.0% |
| IMNM Immunome, Inc. compare | 16.7% |
| ADMA ADMA Biologics Inc compare | 6.26% |
| CLDX Celldex Therapeutics, Inc. | −88.3% |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement